Science and Technology Resources

新型亲和试剂的开发。在过去的一个财政年度，科学和技术资源办公室（OSTR）继续支持一项倡议，以产生高亲和力试剂，作为工具的分子审讯的途径，成为在癌症发展过程中改变。与三家生物技术公司（Beckton Dickinson、Pharmingen、罗克兰Immunochemicals和Epitomics）的合作伙伴关系，已经创造了近200种新的亲和试剂、多克隆抗体和单克隆抗体，可针对CCR研究人员感兴趣的数百种关键癌症相关靶标，成本最低。这些伙伴关系为CCR和NCI节省了100多万美元。参与CCR研究人员生成的所有抗体表征数据都可以通过OSTR和高级生物医学计算中心（ABCC）合作开发的网站提供给相关公司。每个公司在其营销材料中使用这些数据时，抗体被释放用于商业化。我们与Epitomics的合作伙伴关系是生产兔单克隆抗体。已知这些抗体比小鼠单克隆抗体或兔多克隆抗体更稳定且具有更高的亲和力。OSTR与该公司谈判了一份合同，以大大低于目录价格的成本（5，900美元对20，000美元）进入他们的抗体生产管道。与其他合作项目类似，CCR研究人员将被要求对抗体进行表征，并将数据提供给Epitomics进行验证和商业化。OSTR通过弗雷德里克国家实验室（FNL）的蛋白质表征实验室为CCR研究人员支持哺乳动物细胞中的许多蛋白质相互作用筛选。OSTR继续评估所有商业平台基因表达谱和其他高通量基因组技术。为了使CCR研究人员更容易获得最新进展，OSTR与提供基因组和代谢组学分析技术和服务的公司（Affyoung，NanoString，Agilent，Illumina，GenUs，Qiagen，HMT，Metabolon等）建立了许多安排。这些协议大大降低了成本，并为CCR调查人员提供了一种有效和简单的方式来访问这些技术。已经建立了一个补贴计划，提供补贴，以支持CCR研究人员获得先进的基因组学、蛋白质组学、代谢组学和生物信息学技术。这种资助机制有助于扩大CCR实验室有限的研究资金，并使我们的研究人员能够进行成本高昂的实验。许多受资助的项目都在顶级期刊上发表了重要论文。最近，OSTR参与了CCR获得下一代测序技术的努力，包括在37号楼建立一个新的MiSeq Core，供CCR研究人员使用。为了满足CCR对管理和分析大量基因组和蛋白质组数据的快速增长的需求，OSTR与生物信息学公司建立了多个合作伙伴关系。在为NCI节省大量成本的同时，OSTR代表所有NCI研究人员谈判了各种许可协议，以普遍获得用于微阵列实验、蛋白质组学分析研究和基因组分析（包括下一代测序数据）的生物信息学和统计分析的复杂工具。此外，OSTR还为NCI的所有人员提供了一些用于研究途径和生物关联网络的软件应用程序。OSTR继续评估CCR在生物信息学和生物统计学领域的要求。我们继续与Leidos信息系统计划合作，创建CCR专用生物信息学计划，为CCR研究人员提供支持。支持高通量基因组和蛋白质组数据的分析正在通过这个新的核心，这是位于贝塞斯达校园。

Development of Novel Affinity Reagents. During the past fiscal year, the Office of Science and Technology Resources (OSTR) has continued to support an initiative for generating high affinity reagents to serve as tools for molecular interrogation of pathways that become altered during cancer development. Partnerships with three biotechnology companies (Beckton Dickinson, Pharmingen, Rockland Immunochemicals, and Epitomics) have led to the creation of nearly 200 novel affinity reagents, polyclonal, and monoclonal antibodies against hundreds of key cancer related targets of interest to the CCR at minimal cost to CCR investigators. These partnerships represent savings of more than one million dollars to CCR and the NCI. All of the antibody characterization data generated by participating CCR investigators is made available to the companies involved through a Web site developed in a collaboration between the OSTR and the Advanced Biomedical Computing Center (ABCC). Each company uses this data in their marketing material when the antibodies are released for commercialization. Our partnership with Epitomics is for production of rabbit monoclonal antibodies. These antibodies are known to be much more stable and have higher affinities than mouse monoclonal or rabbit polyclonal antibodies. The OSTR negotiated a contract with the company to access their antibody production pipeline at a significantly reduced cost ($5,900 versus $20,000) from the catalog price. Similar to the other collaborative programs, CCR investigators will be required to characterize the antibodies and make data available to Epitomics for validation and commercialization. The OSTR is supporting a number of protein interaction screens in mammalian cells for CCR investigators through the Laboratory of Protein Characterization at the Frederick National Lab (FNL). The OSTR continues to evaluate all commercially available platforms gene expression profiling and other high throughput genomic technologies. To make the latest advances easily accessible to CCR researchers, the OSTR has established a number of arrangements with companies providing genomic and metabolomic profiling technologies and services (Affymetrix, NanoString, Agilent, Illumina, GenUs, Qiagen, HMT, Metabolon, etc.). These agreements have led to far lower cost and an efficient and easy way for CCR investigators to access these technologies. A subsidy program has been established providing subsidies to support CCR investigator access to advanced genomic, proteomic, metabolomic, and bioinformatic technologies. This funding mechanism has helped to extend the limited research dollars available to CCR laboratories and has permitted our researchers to conduct experiments that might otherwise be cost prohibitive. Many of the funded projects have led to important publications in top tier journals. Most recently, the OSTR has been involved in CCR's efforts to access the next generation sequencing technologies, including the setting up of a new MiSeq Core in building 37, which is available to any CCR investigator. In response to CCR's rapidly growing need to manage and analyze large sets of genomic and proteomic data, the OSTR has developed several partnerships with bioinformatics companies. At significant cost savings to NCI, OSTR negotiated a variety of license agreements on behalf of all NCI researchers for universal access to sophisticated tools for bioinformatic and statistical analysis of microarray experiments, proteomic profiling studies, and genomic analysis including next generation sequencing data. In addition, the OSTR has made a number of software applications for the investigation of pathways and biological association networks available to all of NCI. The OSTR continues to assess CCR's requirements in the area of bioinformatics and biostatistics. We continue to work with the Leidos Information Systems Program to create a CCR dedicated Bioinformatics Program to provide support to CCR investigators. Support for analysis of high throughput genomic and proteomic data is being made available through this new core, which is located on the Bethesda campus.